Funding of £1.26M granted to QV Bioelectronics for advancements in novel brain cancer treatment research
Glioblastoma, the most common and aggressive primary brain tumour in adults, continues to pose a significant challenge in the field of oncology, with one of the poorest prognoses. However, a novel treatment approach is on the horizon, as QV Bioelectronics is developing the GRACE Electric Field Therapy device to target brain tumours, particularly glioblastoma.
Preclinical Development
QV Bioelectronics has conducted extensive preclinical studies on the GRACE device, focusing on its ability to deliver electric fields to brain tumour cells non-invasively. Preclinical data suggest that the device can inhibit tumour cell proliferation and potentially enhance the effectiveness of other therapies by disrupting cancer cell division. The device employs a specialized electric field technology designed to penetrate brain tissue safely and target tumour cells more effectively than existing treatments.
Potential Benefits
The primary benefit of the GRACE Electric Field Therapy is offering a non-invasive, targeted treatment alternative for aggressive brain tumours like glioblastoma, which currently have poor prognosis and limited treatment options. Electric field therapy has the potential to reduce tumour growth without the systemic side effects common in chemotherapy. If successful, it could be used as a standalone treatment or in combination with existing therapies to improve patient outcomes.
Plans for Clinical Trials
QV Bioelectronics is currently preparing to initiate clinical trials to evaluate the safety and efficacy of the GRACE device in human patients with brain tumours. These trials are expected to begin after completion of regulatory requirements and sufficient preclinical validation. The company aims to conduct early-phase (Phase 1/2) clinical trials initially, to establish dosing parameters, safety profiles, and preliminary efficacy data.
As of now, the GRACE Electric Field Therapy device remains in the late preclinical stage, with clinical trials upcoming but not yet started. For the most up-to-date information, it is advisable to follow announcements directly from QV Bioelectronics or regulatory filings.
Funding and Partnerships
QV Bioelectronics has secured significant support for the development of the GRACE project. The company has been awarded a 1.26 million GBP grant under the Biomedical Catalyst programme, a vote of confidence in its technology. This funding will support key preclinical, regulatory, and clinical readiness activities for GRACE, helping QV Bioelectronics achieve key milestones as it moves GRACE towards human use.
The University of Edinburgh has contributed to the development of the GRACE project, and a professor from the University of Edinburgh and NHS Lothian has expressed excitement about the prospect of the first in human study of GRACE.
QV Bioelectronics holds multiple granted patents and has secured over 6 million GBP in grant funding and equity investment.
Addressing the Urgent Need for a More Effective Treatment
Current treatments for brain cancer have limited effectiveness and poor outcomes, according to QV Bioelectronics. The company is developing GRACE to address the urgent need for a more effective treatment for brain tumours.
Electric Field Therapy, as used in GRACE, has the potential to significantly improve patient outcomes and quality of life. The GRACE device is the first fully implanted Electric Field Therapy (EFT) system designed to deliver continuous, targeted therapy within the brain.
QV Bioelectronics' CEO, Dr Christopher Bullock, has made a statement regarding the grant, expressing his enthusiasm for the opportunity to bring this promising new approach to treating glioblastoma to patients. With the upcoming clinical trials, we can look forward to seeing the potential benefits of GRACE Electric Field Therapy for those battling this aggressive and devastating disease.
The GRACE Electric Field Therapy, a novel treatment approach developed by QV Bioelectronics, has the potential to significantly improve the health-and-wellness of patients battling aggressive brain tumours like glioblastoma, which currently have poor prognoses and limited medical-conditions treatment options. This non-invasive treatment could potentially reduce tumour growth without the systemic side effects common in cancer chemotherapy, and, if successful, it could be used as a standalone treatment or in combination with existing therapies to improve patient outcomes (Preclinical Development, Potential Benefits).
